Table 1.
Characteristics of cats in each dose group at the time of enrollment, concurrent medications, and adverse events recorded during study
| Dose | ||
|---|---|---|
| 2 μg/kg (n = 6) | 20 μg/kg (n = 3) | |
| Median age, yr (range) | 13.5 (9–17) | 13 (10–15) |
| Median weight, kg (range) | 2.86 (2.45–6.06) | 4.41 (3.54–4.9) |
| Sex | ||
| Female spayed | 5 | 2 |
| Male neutered | 1 | 1 |
| Breed | ||
| DSH | 6 | 2 |
| DLH | 0 | 1 |
| Tumor stagea | ||
| I | 2 | 0 |
| II | 2 | 2 |
| III | 1 | 1 |
| Tumor location | ||
| Mandibular | 4 | 1 |
| Maxillary | 1 | 1 |
| Buccal | 0 | 1 |
| Sublingual/pharyngeal | 1 | 0 |
| Clinical signs | ||
| Reduced appetite | 3 | 2 |
| Weight loss | 3 | 1 |
| Pain | 3 | 1 |
| Visible mass | 2 | 2 |
| Concurrent disease | ||
| CKD | 2 | 1 |
| Hyperthyroidism | 2 | 0 |
| Ocular diseaseb | 0 | 1 |
| Concurrent medications | ||
| Analgesics | 6 | 3 |
| Systemic antibiotics | 3 | 2 |
| Antihistamine | 1 | 0 |
| Topical ocular medications | 0 | 1 |
| Adverse events | ||
| Anorexia | ||
| Grade 1 | 4 | 1 |
| Grade 2 | 2 | 1 |
| Weight loss | ||
| Grade 1 | 5 | 2 |
| Anemia | ||
| Grade 1 | 3 | 1 |
| Grade 2 | 0 | 1 |
| Lethargy | ||
| Grade 1 | 1 | 1 |
| Grade 2 | 1 | 0 |
| Vomiting | ||
| Grade 1 | 1 | 1 |
| Skin ulceration | 0 | 1 |
| Constipation | 0 | 1 |
| Elevated BUN, ALT, AST, CPK | 1 | 0 |
| Hypokalemia | 0 | 1 |
a
Tumor stage not evaluable in one cat as primary tumor was diffuse in nature, precluding repeatable measurements.
b
Cranial nerve III and V denervation left side (possibly tumor related), herpes keratitis, keratoconjunctivitis sicca.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CKD, chronic kidney disease; CPK, creatine phosphokinase; DSH, domestic short hair; DLH, domestic long hair.